Skip to content

Red flags and safety concerns

TL;DR — Colorectal-cancer emergencies come from the tumor (obstruction, perforation, bleeding, sepsis), treatment (neutropenic infection, diarrhea/dehydration, fluoropyrimidine cardiotoxicity, thromboembolism, immune toxicity) and postoperative complications (leak, ileus, abscess). WSES guidance prioritizes resuscitation and sepsis/source control before ideal elective sequencing (Pisano 2018, PMID 30123315). For left-sided obstruction, stent-as-bridge can reduce short-term adverse events and stoma use in selected expert settings, but perforation can compromise oncologic safety (Arezzo 2017, PMID 28392363). Perforated colorectal peritonitis is time critical; longer door-to-antibiotics is associated with higher hospital mortality (Ogawa 2023, PMID 37261545). Pharmacogenetic prevention is actionable: prospective DPYD-guided fluoropyrimidine dosing reduces severe toxicity in variant carriers (Henricks 2018, PMID 30348537). This page is a research safety map, not self-triage advice; suspected acute obstruction, perforation, sepsis, major bleeding, chest pain or severe treatment toxicity requires urgent clinical assessment.

Emergency categories

Category High-risk presentation Immediate clinical objective
Obstruction Distension, pain, vomiting, obstipation Resuscitate, decompress/resect/divert, stage safely
Perforation Peritonitis, free air, sepsis Antibiotics and source control
Bleeding Hemodynamic compromise, symptomatic anemia Stabilize, localize and control
Neutropenic sepsis Fever/systemic illness during cytotoxic therapy Cultures and prompt empiric antibiotics
Diarrhea/dehydration High output, hypotension, renal injury Fluids, infection/toxicity assessment
Cardiac toxicity Chest pain, ischemia/arrhythmia on fluoropyrimidine Stop exposure and urgent cardiac evaluation
Thromboembolism Dyspnea, chest pain, unilateral swelling Confirm and anticoagulate when safe
Postoperative leak Tachycardia, pain, fever, ileus Imaging, antibiotics, drainage/reoperation

Malignant large-bowel obstruction

Obstruction may be the first presentation or progression of known disease. Physiologic risk depends on location, cecal diameter, competence of the ileocecal valve, duration, ischemia/perforation and patient reserve.

CT should define transition, perforation, metastases and competing causes. Colonoscopy is not required before lifesaving decompression when unsafe.

Options

Strategy Best-fit context Major risk
Emergency oncologic resection Fit patient, resectable site, experienced team High morbidity, leak/stoma
Diverting stoma Unstable, low rectal or bridge to staging Additional operation and stoma burden
Self-expanding metal stent (SEMS) bridge Selected left-sided obstruction with expert endoscopy Perforation and tumor dissemination concern
Palliative SEMS Unresectable disease and suitable anatomy Re-obstruction, migration, perforation
Transanal decompression tube Some regional practice Discomfort, failure; less evidence

Randomized-trial meta-analysis found stent bridge reduced adverse events and stoma rate versus emergency surgery for left-sided malignant obstruction (Arezzo 2017, PMID 28392363). High-quality prospective/meta-analytic evidence confirms better short-term surgical outcomes while leaving long-term oncologic uncertainty (Spannenburg 2020, PMID 32418754).

Earlier meta-analyses show heterogeneous technical success and perforation, explaining why results vary by era and operator (Huang 2014, PMID 24170606; De Ceglie 2013, PMID 23845505).

Right-sided obstruction evidence is less mature; meta-analysis suggests bridge-to-surgery feasibility but mostly observational data (Kanaka 2022, PMID 35113211).

Network meta-analysis compares emergency resection, stent and diversion, but indirect evidence inherits selection and local expertise (McKechnie 2023, PMID 36869265).

Stent safety

Concern Mechanism Control
Clinical perforation Wire/device pressure through tumor Expert technique and contraindication review
Silent perforation Microperforation in resection specimen Pathology awareness
Migration Inadequate anchoring/shrinkage Correct sizing; more common after response
Re-obstruction Tumor ingrowth/overgrowth Reintervention or surgery
Anti-VEGF interaction Impaired healing/perforation concern Sequence review

Meta-analysis of long-term outcomes has not resolved whether SEMS compromises cancer survival because perforation, crossover and center skill differ (Matsuda 2015, PMID 25120255; Allievi 2017, PMID 28761765).

Perforation and peritonitis

Perforation can occur at the tumor or proximally from closed-loop pressure. It combines cancer dissemination risk with immediate septic mortality.

WSES guidance prioritizes source control, with operation determined by site, contamination, stability and expertise (Pisano 2018, PMID 30123315).

In perforated colorectal peritonitis, longer door-to-antibiotics time was independently associated with hospital mortality, supporting time-critical sepsis care (Ogawa 2023, PMID 37261545).

Emergency-presentation cohorts show worse morbidity and oncologic outcomes than elective disease, but stage and physiologic collapse confound the comparison (Ogawa 2022, PMID 35847445). Older emergency-surgery series illustrate high risk particularly in right hemicolectomy populations (Wyrzykowski 2005, PMID 16217947).

Clostridium septicum sepsis has a recognized association with colonic malignancy and should trigger evaluation when encountered (Mirza 2009, PMID 19807912).

Bleeding and anemia

Chronic occult bleeding commonly presents as iron-deficiency anemia; acute major hemorrhage is less common. Hemodynamic resuscitation precedes oncologic workup.

Persistent or recurrent bleeding during anti-VEGF treatment, anticoagulation or thrombocytopenia requires drug and local-tumor review. Transfusion decisions depend on physiology, active bleeding and cardiac disease rather than hemoglobin alone.

Postoperative anastomotic leak

Red flags include unexplained tachycardia, fever, escalating pain, ileus, oliguria, confusion or inflammatory deterioration. A normal early examination does not exclude a contained pelvic leak.

CT with IV contrast ± rectal contrast is commonly used; management ranges from antibiotics/drainage to diversion or reoperation. Delay increases sepsis and long-term functional harm.

Low pelvic leaks can worsen LARS even after healing, making leak prevention a survivorship as well as perioperative outcome.

Fluoropyrimidine toxicity and DPYD

5-FU/capecitabine can cause mucositis, diarrhea, myelosuppression, hand-foot syndrome, neurotoxicity and cardiotoxicity. Partial/complete DPD deficiency markedly increases severe/fatal toxicity.

Prospective genotype-guided dosing across four DPYD variants reduced severe toxicity in carriers while preserving exposure targets (Henricks 2018, PMID 30348537). Earlier DPYD*2A implementation also showed safety and cost feasibility (Deenen 2016, PMID 26573078).

Safety strategy What it prevents Limitation
Pretreatment DPYD genotype Known high-risk variants Misses rare variants/non-genetic deficiency
DPD phenotyping Functional deficiency Availability/standardization
Early symptom education Delayed recognition Requires rapid access pathway
Dose individualization Overexposure Underexposure if overly conservative

Fluoropyrimidine cardiotoxicity

Chest pain often occurs during infusion or early capecitabine exposure and may reflect coronary vasospasm, ischemia, arrhythmia or cardiomyopathy. Rechallenge can recur and should be specialist-led.

Raltitrexed has been used as an alternative in patients with cardiac history or fluoropyrimidine cardiotoxicity, supported mainly by nonrandomized safety evidence (Kelly 2013, PMID 23583220).

Irinotecan diarrhea and UGT1A1

Acute cholinergic diarrhea during infusion differs from delayed secretory/mucosal diarrhea. Delayed diarrhea can cause dehydration, renal injury, electrolyte loss and sepsis.

UGT1A1 reduced-function variants increase irinotecan neutropenia risk, especially at higher doses; historical pharmacogenetic review supports dose/context dependence (Hahn 2006, PMID 17090741). Contemporary host-genetic profiling seeks to integrate UGT1A1 with DPYD rather than treat each drug in isolation (Cecchin 2018, PMID 30075835).

Oxaliplatin safety

Acute cold dysesthesia and chronic cumulative sensory neuropathy are distinct. Laryngopharyngeal dysesthesia can feel like airway compromise without hypoxia, but true allergy must be excluded.

Persistent numbness, balance impairment or functional loss should trigger dose modification before irreversible accumulation. Preventive supplements lack reliable evidence (Kuriyama 2018, PMID 29280005).

Oxaliplatin hypersensitivity can escalate with repeated exposure; rechallenge/desensitization requires a controlled setting.

Bevacizumab and antiangiogenic safety

Event Risk context
Hypertension Pre-existing hypertension and cumulative therapy
Proteinuria Renal disease
Arterial event Vascular disease/older age
Venous thrombosis Cancer baseline plus drug effect
Bleeding Tumor, anticoagulation, recent procedure
GI perforation Obstruction, inflammation, prior radiation/surgery
Wound failure Perioperative timing

Meta-analysis confirms increased hypertension and thromboembolism with bevacizumab-containing colorectal therapy (Chitkara 2023, PMID 38069531). Earlier randomized-trial meta-analysis supports efficacy with increased vascular/toxicity burden (Cao 2009, PMID 19184059; Botrel 2016, PMID 27558497).

Anti-EGFR safety

Acneiform rash, paronychia, fissures, hypomagnesemia, diarrhea and infusion reaction are common. Rash can impair sleep, work and infection risk; prophylactic moisturizers, sunscreen, topical steroid and oral tetracycline strategies reduce severity.

Hypomagnesemia can cause cramps/arrhythmia and may persist after treatment. Electrolytes require serial monitoring.

Checkpoint therapy can cause colitis, hepatitis, pneumonitis, endocrinopathy, nephritis, myocarditis and neurologic toxicity. Timing can be delayed and multi-organ.

Diarrhea in a patient receiving checkpoint therapy has infectious, chemotherapy, radiation, obstruction/overflow and immune-colitis differentials. Steroids given without excluding perforation/infection can harm; delayed immune treatment can also harm.

Dual nivolumab–ipilimumab improves dMMR efficacy but increases immune toxicity compared with PD-1 alone (André 2025, PMID 39874977).

Neutropenic fever

Fever/systemic illness during myelosuppressive therapy is a time-critical infection syndrome. Risk rises with triplet chemotherapy, older age, comorbidity, prior infection and poor marrow reserve.

Outpatient versus inpatient management requires a validated risk assessment and reliable rapid return. Growth-factor prophylaxis depends on regimen and individual febrile-neutropenia risk.

Venous thromboembolism

Colorectal cancer, surgery, hospitalization and systemic therapy all increase VTE risk. Treatment balances recurrence against GI bleeding and thrombocytopenia.

Incidental pulmonary embolism on staging imaging is clinically relevant. Anticoagulation choice depends on bleeding lesion, renal function, drug interactions and planned procedures.

Stoma emergencies

Problem Red flag
High-output ileostomy Dehydration, dizziness, oliguria, rising creatinine
Obstruction Cramping, vomiting, no output, swelling
Ischemia Dark/necrotic stoma
Retraction/leak Severe skin breakdown and inability to seal
Prolapse Ischemia, obstruction or inability to reduce
Parastomal hernia Pain, obstruction, appliance failure

Early specialist stoma access can prevent dehydration and readmission.

Surveillance red flags

New persistent focal pain, weight loss, bleeding, obstructive symptoms, jaundice, dyspnea or neurologic symptoms warrant evaluation even when scheduled imaging/CEA is reassuring. CEA has incomplete sensitivity (Liemburg 2021, PMID 33704843).

In watch-and-wait, missed endoscopy/MRI undermines safety; local regrowth is most salvageable when detected early (Yuval 2021, PMID 34389102).

Open questions

  • Which left-obstruction subgroup has net oncologic benefit from stent bridge? (Arezzo 2017, PMID 28392363)
  • Can expanded DPYD/phenotype testing eliminate most severe fluoropyrimidine toxicity without underdosing? (Henricks 2018, PMID 30348537)
  • Which biomarkers predict bevacizumab perforation in obstructed or irradiated bowel? (Chitkara 2023, PMID 38069531)
  • What surveillance safety system prevents lost-to-follow-up in watch-and-wait? (Yuval 2021, PMID 34389102)
  • Can remote symptom monitoring reduce emergency admissions during triplet/late-line therapy? (André 2025, PMID 39874977)

References

  1. Pisano M, et al. 2017 WSES guidelines on colon and rectal cancer emergencies: obstruction and perforation. World J Emerg Surg. 2018;13:36. PMID 30123315
  2. Arezzo A, et al. Stent as bridge to surgery for left-sided malignant colonic obstruction reduces adverse events and stoma rate compared with emergency surgery: results of a systematic review and meta-analysis of randomized controlled trials. Gastrointest Endosc. 2017;86(3):416-426. PMID 28392363
  3. Ogawa K, et al. Prolonged door-to-antibiotics time is associated with high hospital mortality in patients with perforated colorectal peritonitis. Langenbecks Arch Surg. 2023;408(1):220. PMID 37261545
  4. Henricks LM, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19(11):1459-1467. PMID 30348537
  5. Spannenburg L, et al. Surgical outcomes of colonic stents as a bridge to surgery versus emergency surgery for malignant colorectal obstruction: A systematic review and meta-analysis of high quality prospective and randomised controlled trials. Eur J Surg Oncol. 2020;46(8):1404-1414. PMID 32418754
  6. Huang X, et al. Preoperative colonic stents versus emergency surgery for acute left-sided malignant colonic obstruction: a meta-analysis. J Gastrointest Surg. 2014;18(3):584-91. PMID 24170606
  7. De Ceglie A, et al. A meta-analysis of endoscopic stenting as bridge to surgery versus emergency surgery for left-sided colorectal cancer obstruction. Crit Rev Oncol Hematol. 2013;88(2):387-403. PMID 23845505
  8. Kanaka S, et al. Colonic stent as a bridge to surgery versus emergency resection for right-sided malignant large bowel obstruction: a meta-analysis. Surg Endosc. 2022;36(5):2760-2770. PMID 35113211
  9. McKechnie T, et al. Management of left-sided malignant colorectal obstructions with curative intent: a network meta-analysis. Surg Endosc. 2023;37(6):4159-4178. PMID 36869265
  10. Matsuda A, et al. Comparison of long-term outcomes of colonic stent as "bridge to surgery" and emergency surgery for malignant large-bowel obstruction: a meta-analysis. Ann Surg Oncol. 2015;22(2):497-504. PMID 25120255
  11. Allievi N, et al. Endoscopic Stenting as Bridge to Surgery versus Emergency Resection for Left-Sided Malignant Colorectal Obstruction: An Updated Meta-Analysis. Int J Surg Oncol. 2017;2017:2863272. PMID 28761765
  12. Ogawa K, et al. Evaluation of clinical outcomes with propensity-score matching for colorectal cancer presenting as an oncologic emergency. Ann Gastroenterol Surg. 2022;6(4):523-530. PMID 35847445
  13. Wyrzykowski AD, et al. Emergent right hemicolectomies. Am Surg. 2005;71(8):653-6; discussion 656-7. PMID 16217947
  14. Mirza NN, McCloud JM, Cheetham MJ. Clostridium septicum sepsis and colorectal cancer - a reminder. World J Surg Oncol. 2009;7:73. PMID 19807912
  15. Deenen MJ, et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol. 2016;34(3):227-34. PMID 26573078
  16. Kelly C, et al. Use of raltitrexed as an alternative to 5-fluorouracil and capecitabine in cancer patients with cardiac history. Eur J Cancer. 2013;49(10):2303-10. PMID 23583220
  17. Hahn KK, Wolff JJ, Kolesar JM. Pharmacogenetics and irinotecan therapy. Am J Health Syst Pharm. 2006;63(22):2211-7. PMID 17090741
  18. Cecchin E, et al. Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation. Drug Resist Updat. 2018;39:18-40. PMID 30075835
  19. Kuriyama A, Endo K. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Support Care Cancer. 2018;26(4):1051-1059. PMID 29280005
  20. Chitkara A, et al. Risks of hypertension and thromboembolism in patients receiving bevacizumab with chemotherapy for colorectal cancer: A systematic review and meta-analysis. Cancer Med. 2023;12(24):21579-21591. PMID 38069531
  21. Cao Y, et al. A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis. 2009;24(6):677-85. PMID 19184059
  22. Botrel TEA, et al. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16(1):677. PMID 27558497
  23. André T, et al. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial. Lancet. 2025;405(10476):383-395. PMID 39874977
  24. Liemburg GB, et al. Diagnostic accuracy of follow-up tests for detecting colorectal cancer recurrences in primary care: A systematic review and meta-analysis. Eur J Cancer Care (Engl). 2021;30(5):e13432. PMID 33704843
  25. Yuval JB, Garcia-Aguilar J. Watch-and-wait Management for Rectal Cancer After Clinical Complete Response to Neoadjuvant Therapy. Adv Surg. 2021;55:89-107. PMID 34389102